MD, PhD · Board-certified in pathology
I study how bioenergetics regulates gene expression.
Postdoctoral Fellow, Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center — laboratory of Craig B. Thompson.
Physician-Scientist Training Program, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine.
Metabolism is usually treated as the cell's power supply. I study it as a source of regulatory information — where a metabolite's stereochemistry, or the route by which ATP reaches the nucleus, determines which genes a cell can open and which fate it takes.
I did my M.D./Ph.D. at NYU, where my thesis work with Dan Littman established how the Cd4 locus is heritably silenced in cytotoxic T cells, using CD4 silencing as a lineage marker for epigenetic memory. I then trained as a physician-scientist at Weill Cornell, in anatomic pathology and the Physician-Scientist Training Program, where I remain a trainee. I work in Craig Thompson’s laboratory at Memorial Sloan Kettering at the interface of metabolism, chromatin, and antitumor immunity, supported by a Tow Foundation Postdoctoral Fellowship.
In my postdoctoral work (Ng et al., Cell, 2026), I showed that D-alpha-hydroxybutyrate — a short-chain alpha-hydroxy acid of microbial origin — acts as a signaling molecule that switches CD8 T cells from glycolysis to fatty-acid-supported oxidative phosphorylation, builds a phosphocreatine reserve, and drives ATP-dependent chromatin remodeling at effector loci, enhancing antitumor function in both mouse and human T cells.
I follow ATP delivery rather than the provision of substrates such as acetyl-CoA for acetylation or SAM for methylation: blocking ATP synthase leaves DAHB-induced histone acetylation intact but abolishes effector gene induction.
Three questions organize the laboratory I am building: how ATP delivery to chromatin is regulated in space and time; how D-2-hydroxyacids set bioenergetics both within a cell and across the whole animal; and how metabolic stress signaling selects which effector genes a T cell expresses. Together they point toward new therapeutic strategies for antitumor immunity and metabolic disease.
Chromatin remodeling consumes ATP, but ATP does not travel freely through a crowded nucleus. I am testing whether the creatine/phosphocreatine shuttle is what delivers it — mapping creatine kinase B and its partners at chromatin, reading nuclear ATP directly with targeted sensors, and then engineering orthogonal phosphagen circuits into T cells: a cell-engineering strategy that modifies energy supply rather than signaling.
D-alpha-hydroxybutyrate acts through its stereochemistry rather than through its metabolism. The mirror-image L form does not substitute, and my data show the sensor is not LDHD, the enzyme that consumes it. I am identifying the protein that reads the D configuration — and following the same chemistry outside the immune system, where oral DAHB limits diet-induced weight gain through a mechanism that requires LDHD in the intestinal epithelium.
Energetic stress engages several sensors at once — the integrated stress response, AMPK, mTORC1, the heat-shock arm — and my published data show the ISR alone does not account for which effector genes open. I am mapping which stress kinases are actually engaged rather than assuming which ones matter, and doing it cell by cell rather than in bulk, where opposing signals average away.
Complete list: ORCID · Google Scholar
cpn9005@med.cornell.edu
ngc3@mskcc.org
Rockefeller Research Laboratories, Room 469
411 East 67th Street, New York, NY 10065